DXCM|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.67 | - | - |
| Q2'26 | $0.61 | $0.70 | +15.1% |
| Q1'26 | $0.47 | $0.56 | +19.0% |
| Q4'25 | $0.48 | $0.68 | +42.8% |
| Q3'25 | $0.57 | $0.61 | +7.5% |
| Q2'25 | $0.44 | $0.48 | +8.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.4B | - | - |
| Q2'26 | $1.3B | $1.3B | +1.4% |
| Q1'26 | $1.2B | $1.2B | +1.5% |
| Q4'25 | $1.2B | $1.3B | +6.5% |
| Q3'25 | - | $1.2B | - |
| Q2'25 | - | $1.2B | - |
Market Data
DXCM Stock Snapshot
DXCM is currently trading at $83.99, giving DexCom, Inc. a market cap of 31.98B and a P/E ratio of 32.0. Today's range spans $82.09–$85.06, with shares opening at $82.40 and moving down $0.76 (0.9%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 47/100.
Over the past year DXCM has traded between $54.11 and $87.85 - the current price is +55.2% off the 52-week low and -4.4% from the high. 38 analysts cover the stock with a Buy consensus and a mean 12-month target of $93.44 (range $79.00–$115.00), implying upside of +11.3%.
What DXCM has right now - BUY signal, 95/100 technical score, neutral sentiment at 47/100, price $83.99 (near 52-week highs) - is the profile that shows up in screens looking for Healthcare growth stories with technical confirmation. (P/E: 32.0) At 31.98B in capitalization, the risk/reward of a setup like this is often better than in mega-cap peers where the same signal translates to a smaller percentage move. Range: $54.11–$87.85.
What makes DXCM's BUY setup (95/100) particularly actionable at 31.98B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $83.99 (near 52-week highs in $54.11–$87.85), with sentiment running neutral at 47/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: DexCom, Inc. (DXCM)
DexCom, Inc. is a leading medical technology firm focused on continuous glucose monitoring (CGM) systems, a critical component in modern diabetes management. The company's integrated devices, such as the Dexcom G6 and G7, provide real-time glucose data to patients and healthcare providers, facilitating better treatment decisions. DexCom's strategy involves direct engagement with endocrinologists and physicians to drive adoption of its innovative CGM solutions.
The company's financial performance shows a pattern of revenue growth, with Q4 2025 revenue reaching $1.26 billion, up from $1.11 billion in Q4 2024. While earnings per share (EPS) have shown some variability against analyst estimates, with beats in Q4 2025 and Q2 2025, the overall trend indicates operational expansion. Management's reaffirmation of 2026 revenue guidance suggests confidence in sustained double-digit growth.
Recent market sentiment appears positive, with institutional investors increasing their holdings in DexCom. This optimism is fueled by the accelerating adoption of CGMs among users of GLP-1 drugs, a trend expected to be a significant growth driver. The successful rollout and market penetration of the G7 system, alongside efforts to secure broader insurance coverage, are key factors to watch.
CGM Market Leadership
DexCom holds a dominant position in the continuous glucose monitoring market with its G6 and G7 devices.
The company's integrated systems offer real-time data crucial for effective diabetes management.
Direct engagement with healthcare professionals drives product adoption and market penetration.
GLP-1 Synergies
There is accelerating CGM adoption among patients utilizing GLP-1 drugs for diabetes and weight management.
This trend represents a significant potential growth catalyst for DexCom's user base and revenue.
The company is well-positioned to capitalize on this expanding patient population.
Product Innovation & Expansion
The Dexcom G7 system is central to the company's ongoing product roadmap and market strategy.
Expansion into new product lines like Dexcom ONE and Stelo aims to broaden accessibility.
Integration with third-party digital health applications via the Real-Time API enhances ecosystem value.
Financial Performance
Consistent year-over-year revenue growth, exemplified by Q4 2025's $1.26 billion in revenue.
Management has reaffirmed 2026 revenue guidance, projecting continued double-digit expansion.
Focus remains on driving adoption and expanding market share to sustain growth trajectory.
Institutional Confidence
Recent activity shows institutional funds initiating and increasing positions in DexCom.
This indicates growing confidence in the company's future growth prospects and market position.
Positive sentiment is linked to the company's strategic initiatives and market trends.
Positioning DXCM
Consider adding to exposure as DexCom demonstrates sustained acceleration in CGM adoption, particularly driven by GLP-1 users. Monitor progress on international expansion and securing enhanced insurance coverage, which are key to unlocking further growth. Reducing exposure may be warranted if competitive pressures intensify significantly or if the company faces setbacks in its G7 rollout or market access initiatives.
Key Metrics for DXCM
DexCom's growth hinges on expanding CGM adoption and successful product launches. Investors should monitor key operational and market penetration metrics.
CGM User Growth: Measures the increase in active users of DexCom's continuous glucose monitoring systems. Accelerating user growth indicates strong market penetration and demand; slowing growth could signal competitive pressure or market saturation. This is crucial for DXCM as it directly impacts revenue and market share in the diabetes management space.
Revenue Growth: Tracks the year-over-year increase in DexCom's total sales. Strong, consistent revenue growth is essential for a medical device company like DXCM, demonstrating market acceptance and expansion. Declining or decelerating revenue growth would be a significant concern for investors, potentially impacting the stock's valuation.
Gross Margin: Represents the percentage of revenue remaining after accounting for the cost of goods sold. Expanding gross margins suggest improved manufacturing efficiency or pricing power for DXCM; contracting margins could indicate rising production costs or competitive pricing pressures. This metric is vital for assessing DXCM's profitability and operational efficiency.
New Product Adoption: Monitors the uptake and sales contribution of newer CGM devices like the G7. Strong adoption of new products is critical for DXCM's long-term growth and competitive positioning. Lower-than-expected adoption rates could signal product issues or market resistance, negatively affecting investor sentiment.
International Sales Growth: Measures the revenue growth from markets outside the United States. Increasing international sales demonstrate DXCM's ability to expand its global footprint and diversify revenue streams. Slowing international growth could indicate challenges in market access or regulatory hurdles, impacting DXCM's overall growth potential.
What Moves DXCM Stock?
DexCom's stock performance is primarily driven by the expanding adoption of its continuous glucose monitoring (CGM) systems, particularly among diabetes patients and those using new weight-loss medications.
CGM Adoption
DexCom's core business relies on the increasing acceptance and utilization of its G6 and G7 CGM devices for diabetes management. The company's strategy involves direct engagement with healthcare providers and patients to highlight the benefits of real-time glucose data.
Strong uptake of these devices translates directly into revenue growth and market share gains. Any acceleration in adoption, fueled by product innovation or expanded insurance coverage, tends to drive the stock higher, while slower growth can pressure valuations.
GLP-1 Synergy
The burgeoning use of GLP-1 drugs for weight management presents a significant new market for CGM technology. Many patients on these medications are also managing or at risk for diabetes, creating a natural overlap for DexCom's products.
This trend is a key growth catalyst, as it expands the addressable market for CGM systems beyond traditional diabetes patients. Positive developments or data supporting this synergy are likely to boost investor confidence and the stock price.
Product Roadmap
DexCom's future growth is underpinned by its ongoing product development, including the G7 system and potential new offerings like Dexcom ONE and Stelo. These innovations aim to improve user experience and broaden market access.
Successful product launches and positive clinical outcomes, as showcased at events like ATTD 2026, reinforce the company's competitive position. Delays or competitive pressures on its product pipeline could negatively impact investor sentiment and stock performance.
Key insight: The expanding reach of continuous glucose monitoring, particularly its integration with the growing GLP-1 drug market, is the paramount driver for DexCom's stock. Continued innovation and successful market penetration will be key to sustained growth.
Risk Factors
DexCom's risks are primarily tied to the competitive landscape of diabetes management technology, regulatory hurdles, and the successful adoption of its next-generation products.
- Competition Risk
The continuous glucose monitoring (CGM) market is becoming increasingly competitive with established players and new entrants. Intense competition could pressure DexCom's pricing power and market share. This risk would materialize if competitors launch superior products or significantly undercut DexCom's pricing.
- Regulatory Approval
DexCom relies on regulatory bodies like the FDA for approval of its new devices and software updates. Delays or rejections in obtaining these approvals can hinder product launches and revenue growth. This risk is present whenever new product iterations or expanded indications are sought.
- Reimbursement Risk
The company's revenue is significantly influenced by insurance coverage and reimbursement rates for its CGM systems. Changes in payer policies or reduced reimbursement could impact patient access and sales volumes. This risk becomes acute if major insurers alter their coverage decisions.
- Product Adoption
DexCom's growth depends on the widespread adoption of its G7 system and future innovations. If these products fail to gain traction with physicians and patients, or if integration with other diabetes management tools is challenging, it could slow revenue expansion. This risk would manifest if uptake of new devices is slower than anticipated.
- Supply Chain Disruptions
As a medical device manufacturer, DexCom is susceptible to disruptions in its global supply chain for components and manufacturing. Such disruptions could lead to product shortages and impact its ability to meet demand. This risk is heightened during periods of global economic instability or geopolitical events.
Analyst Price Targets for DXCM
Here's where sell-side analysts stand on DXCM right now, based on the latest ratings DailyIQ has tracked.
Reflects the most recently tracked analyst ratings for DXCM and may lag real-time updates. Not a recommendation to buy or sell.
DXCM Competitive Positioning
DexCom, Inc. (DXCM) is tracked alongside these names in Medical Devices on DailyIQ.
DXCM Recent Earnings History
- Q4 2025
EPS: $0.68 actual vs $0.48 estimate (beat) · Revenue: $1,260M actual vs $1,183M estimate
- Q3 2025
EPS: $0.61 actual vs $0.57 estimate (beat) · Revenue: $1,209M actual
- Q2 2025
EPS: $0.48 actual vs $0.44 estimate (beat) · Revenue: $1,157M actual
- Q1 2025
EPS: $0.32 actual vs $0.33 estimate (miss) · Revenue: $1,036M actual
- Q4 2024
EPS: $0.45 actual vs $0.5 estimate (miss) · Revenue: $1,114M actual
Frequently Asked Questions About DXCM
Is DexCom (DXCM) stock a good investment for long-term growth?
DexCom's investment thesis centers on its leading position in the growing continuous glucose monitoring (CGM) market. The company benefits from increasing diabetes prevalence, technological advancements in its devices, and expanding insurance coverage. Investors often consider its strong product pipeline and potential for international market penetration as key growth drivers.
What factors drive DexCom's (DXCM) stock price?
The stock price of DexCom is influenced by several key factors, including the adoption rates of its CGM systems, particularly the G7, and the expansion of its user base. Positive clinical data, new product launches, and regulatory approvals are significant catalysts. Additionally, broader market sentiment towards healthcare technology stocks and competitive developments within the diabetes management space can impact its valuation.
Does DexCom (DXCM) pay a dividend?
Currently, DexCom (DXCM) does not pay a dividend to its shareholders. The company prioritizes reinvesting its earnings back into research and development, expanding its manufacturing capabilities, and pursuing strategic growth initiatives. Investors seeking income through dividends would need to look at other companies in the sector.
What are the risks associated with investing in DexCom (DXCM) stock?
Key risks for DexCom (DXCM) include intense competition from established medical device companies and emerging players, potential regulatory hurdles for new products, and challenges in securing favorable reimbursement from insurance providers. Manufacturing disruptions, supply chain issues, and the company's reliance on key technology also present potential headwinds.
How is DexCom's (DXCM) valuation assessed by investors?
Investor assessment of DexCom's valuation often hinges on its revenue growth rates, market share in the CGM sector, and future earnings potential. Metrics like the price-to-sales (P/S) ratio and forward price-to-earnings (P/E) ratio are commonly used, especially given its growth-oriented nature. Analysts also scrutinize its competitive positioning and the long-term demand for diabetes management technologies.
What is the outlook for DexCom's (DXCM) G7 system and future products?
The Dexcom G7 system is expected to be a significant driver of future growth, offering improved features and user experience compared to previous models. The company is also actively developing its product roadmap, which may include next-generation CGM technologies and expanded applications. Success in international markets and broader adoption by individuals with type 2 diabetes are key aspects of its forward outlook.
How does the rise of GLP-1 drugs impact DexCom (DXCM)?
The increasing use of GLP-1 drugs for diabetes and weight management presents a significant growth opportunity for DexCom. Many patients using these medications also benefit from continuous glucose monitoring to manage their metabolic health. This trend is expected to accelerate CGM adoption, potentially expanding DexCom's addressable market and driving higher sales volumes.
What is DexCom's (DXCM) strategy for international expansion?
DexCom's international expansion strategy involves securing regulatory approvals in new markets, establishing distribution partnerships, and adapting its products to meet local healthcare needs and reimbursement landscapes. The company aims to increase global access to its CGM technology, particularly in regions with a high prevalence of diabetes. Success in these markets could provide substantial long-term revenue growth.
How does DexCom (DXCM) manage competition in the medical device sector?
DexCom manages competition through continuous innovation, focusing on developing user-friendly and technologically advanced CGM systems. The company also invests heavily in clinical research to demonstrate the value of its devices and works to build strong relationships with healthcare providers and payers. Maintaining a robust intellectual property portfolio is also a key part of its competitive strategy.
Learn More
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.